NCT01402401View on ClinicalTrials.gov

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Advanced Gastric Cancer
Interventions
DRUG

AUY922

DRUG

Trastuzumab

Trial Locations (15)

3000

Novartis Investigative Site, Leuven

11042

Clinical Research Alliance, Lake Success

33075

Novartis Investigative Site, Bordeaux

41100

Novartis Investigative Site, Modena

51092

Novartis Investigative Site, Reims

68305

Novartis Investigative Site, Mannheim

74078

Novartis Investigative Site, Heilbronn

90095

University of California at Los Angeles UCLA LeConte Location, Los Angeles

77030-4009

University of Texas/MD Anderson Cancer Center UT SC, Houston

06189

Novartis Investigative Site, Nice

277-8577

Novartis Investigative Site, Kashiwa

060-8648

Novartis Investigative Site, Sapporo

110 744

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY